Key facts
- Aer Therapeutics’s last known valuation is $58.0M (Mar 2025).
- It has raised $48.0M across 2 recorded rounds; the latest was Early Stage VC ($5.0M) in Jan 2025.
- Notable investors include National Institutes of Health, OrbiMed, Canaan Partners, Hatteras Venture Partners, NovaUCD — 6 tracked in total.
- Aer Therapeutics has filed 2 Form Ds with the SEC since 2022, most recently Feb 2025 ($5.0M sold to 15 investors).
- Status: Privately Held (backing).
- ·Post-money valuations for all 2 rounds
- ·The complete investor list — 6 names
- ·Watchlist + deal alerts for Aer Therapeutics
Funding rounds
2 roundsAbout Aer Therapeutics
Operator of a biopharmaceutical company intended to treat lung disease with excess mucus and mucus plugs. The company focuses on treating respiratory diseases with unmet needs, such as chronic obstructive pulmonary disease (COPD), cystic fibrosis, and asthma, enabling researchers to advance the treatment paradigm for mucus-mediated lung diseases.
- Sector
- Healthcare
- HQ
- Durham, United Kingdom
- Founded
- 2014
- Employees
- 10
- Website
- aertherapeutics.com/
- Ownership
- Privately Held (backing)
Aer Therapeutics doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Aer Therapeutics shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Aer Therapeutics in its N-PORT filings yet. We sweep new filings monthly.